title: Asymmetric dimethylarginine in hemodialysis, hemodiafiltration, and peritoneal dialysis.
abstract: Asymmetric dimethylarginine (ADMA) is a mediator of endothelial dysfunction. Production and elimination of ADMA may be affected by the type of renal replacement therapy used and oxidative stress. Plasma ADMA, advanced glycation end products (AGE), and homocysteine were assessed in 59 subjects: 20 hemodialysis (HD) patients, 19 patients undergoing peritoneal dialysis (PD), and 20 controls. Results were compared between the groups. The effect of 8 weeks of HD and high-volume predilution hemodiafiltration (HDF) was compared in a randomized study. HD patients showed higher ADMA (1.20 [0.90-1.39 micromol/L]) compared to controls (0.89 [0.77-0.98], P < 0.01), while ADMA in PD did not differ from controls (0.96 [0.88-1.28]). AGE and homocysteine were highest in HD, lower in PD (P < 0.01 vs. HD), and lowest in controls (P < 0.001 vs. HD and PD). PD patients had higher residual renal function than HD (P < 0.01). The decrease in ADMA at the end of HD (from 1.25 [0.97-1.33] to 0.66 [0.57-0.73], P < 0.001) was comparable to that of HDF. Switching from HD to HDF led to a decrease in predialysis homocysteine level in 8 weeks (P < 0.05), while ADMA and AGE did not change. Increased ADMA levels in patients undergoing HD, as compared to PD, may be caused by higher oxidative stress and lower residual renal function in HD. Other factors, such as diabetes and statin therapy, may also be at play. The decrease in ADMA at the end of HD and HDF is comparable. Switching from HD to HDF decreases in 8 weeks the predialysis levels of homocysteine without affecting ADMA.
authors.affiliation: Internal Department I, Charles University, Medical School and Teaching Hospital, Alej Svobody 80, Plzen, Czech Republic. eiselt@fnplzen.cz
authors.forename: Jaromír
authors.initials: J
authors.lastname: Eiselt
authors.forename: Daniel
authors.initials: D
authors.lastname: Rajdl
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Racek
authors.forename: Romana
authors.initials: R
authors.lastname: Siroká
authors.forename: Ladislav
authors.initials: L
authors.lastname: Trefil
authors.forename: Sylvie
authors.initials: S
authors.lastname: Opatrná
mesh_terms: D000368:Aged; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010530:Peritoneal Dialysis; D006435:Renal Dialysis
chemical_list: D017127:Glycation End Products, Advanced; D006710:Homocysteine; C018524:N,N-dimethylarginine; D001120:Arginine